 | |
| Clinical data | |
|---|---|
| Other names | HU-308, HU308, PPP-003, ARDS-003 |
| Drug class | CB2 receptor agonist |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Liver |
| Excretion | Kidneys |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C27H42O3 |
| Molar mass | 414.630 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Onternabez (also known asHU-308,HU308,PPP-003, andARDS-003) is asynthetic cannabinoid that acts as a potentcannabinoidagonist. It is highly selective for thecannabinoid-2 receptor (CB2 receptor) subtype, with a selectivity more than 5,000 times greater for the CB2 receptor than theCB1 receptor.[1][2][3] Thesynthesis and characterization of onternabez took place in the laboratory ofRaphael Mechoulam at theHebrew University of Jerusalem (the HU in HU-308) in the late 1990s. Thepinene dimethoxy-DMH-CBD derivative onternabez was identified as a potent peripheral CB2-selective agonist inin vitro and animal studies in 1990[1] and 1999.[2]
Onternabez is non-psychoactive and not scheduled at the federal level in the United States.[4] It is a Schedule Icontrolled substance in the state ofFlorida making it illegal to buy, sell, or possess there.[5]
